Navigation Links
ViroPharma Incorporated Reports Fourth Quarter and Full Year 2011 Financial Results
Date:2/28/2012

EXTON, Pa., Feb. 28, 2012 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) reported today its financial results for the fourth quarter and year ended December 31, 2011.

In 2011, we:

  • Achieved a record $544 million in annual net product sales, including $251 million in net sales of Cinryze® (C1 esterase inhibitor [human]), and $289 million in net sales of Vancocin® (Vancomycin Hydrochloride Capsules, USP);
  • Attained non-GAAP adjusted net income of $182 million; GAAP net income reached $141 million;
  • Delivered positive cash flows from operations of $171 million;
  • Utilized $170 million of cash to repurchase 9.2 million shares of ViroPharma stock; and
  • Finished the year with working capital of $537 million as of December 31, 2011, including cash, cash equivalents and short-term investments of $460 million.

  • Net sales were $145.6 million and $544.4 million for the fourth quarter and year ended December 31, 2011, respectively, as compared to $121.6 million and $439.0 million in the comparative periods of 2010, respectively.  This represents 20 percent growth in the fourth quarter and 24 percent growth for the year in net product sales. The fourth quarter Cinryze demand was satisfied through net sales of $66.7 million as reported and a reduction in the channel of about a week.

    "As evidenced by our financial and operational performance throughout the year, 2011 was clearly the most successful period in the history of our company," stated Vincent Milano, ViroPharma's chief executive officer. "Among the highlights were the approvals and launches of Cinryze and Buccolam® (midazolam, oromucosal solution) in Europe, continued strong growth of Cinryze in the U.S., and the approval of our Vancocin sNDA leading to modernized labeling and, we believe, three years of exclusivity.  We also significantly broade
    '/>"/>

    SOURCE ViroPharma Incorporated
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12

    Related biology technology :

    1. ViroPharma to Present at Three September Healthcare Conferences
    2. ViroPharma to Present at Three October Healthcare Conferences
    3. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
    4. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
    5. ViroPharma to Present at Three November Healthcare Conferences
    6. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
    7. ViroPharma Improves Financial Position Through Repurchase of $45 Million Principal Amount of Senior Convertible Notes
    8. ViroPharma to Release 2009 First Quarter Financial Results on April 29, 2009
    9. ViroPharma Incorporated Reports First Quarter 2009 Financial Results
    10. ViroPharma Incorporated Honored by the National Organization for Rare Disorders
    11. ViroPharma to Present at Two June Healthcare Conferences
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/22/2014)... Shimadzu Scientific Instruments introduces its Open Solution QuantAnalytics(TM) ... management and clinical markets. The software increases the speed ... users to highlight and review results that are of ... to filter results by group or based on a ... need to sift through analytes of no interest. In ...
    (Date:10/22/2014)... UAE (PRWEB) October 22, 2014 Grace ... science and healthcare projects, announces the addition of ... DCH to its advisory team. Dr. Siddiqui will provide ... , A graduate of University College Medical ... subsequently degreed in medicine in 2001. With further certification ...
    (Date:10/22/2014)... , Oct. 22, 2014 /PRNewswire/ - iCo Therapeutics ("iCo" ... announced next steps for its Oral Amphotericin B ... its in vitro work involving samples ... now plans to complete pre clinical studies and ... Phase 1A clinical trial, utilizing approximately $700,000 of ...
    (Date:10/20/2014)... The report “Pharmacy Automation Systems Market ... Labeling Systems, Table-top Counters) by End-user (Inpatient Pharmacy ... Trends to 2019” analyzes and studies the major ... Europe, Asia-Pacific, and the Rest of the World ... figures spread through 300 pages and in-depth TOC ...
    Breaking Biology Technology:Shimadzu Releases QuantAnalytics Open Access LCMS Software Package for Clinical Applications 2Dr. Yousef Siddiqui joins the Grace Century Advisory Team 2iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 2iCo Therapeutics Announces Advancement of Oral Amphotericin B Program 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 2Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 4
    ... ... Intellectual Property, FULLERTON, Calif., Nov. 28 Beckman Coulter,Inc. ... and,automate complex biomedical testing announced today that it has entered,into an ... spin out of Lumigen, Inc., effected prior to Beckman,Coulter,s acquisition of ...
    ... Cambridge Research &,Instrumentation (CRi) announced today that ... of allowance for their patent application number,10/669,101, for ... patent covers the use of multispectral imaging combined,with ... of,fluorophores in a living mammal. The unmixing of ...
    ... 1-41 has significant ... and anti-amnesic benefits, GENEVA, Nov. 28 /PRNewswire-FirstCall/ - ... announce promising developments with,ANAVEX 1-41, the company,s lead drug ... 1-41 prevented oxidative stress,which damages and destroys cells and ...
    Cached Biology Technology:Beckman Coulter to Acquire Exclusive Rights to Break-Through Technologies 2US Patent and Trademark Office Allows CRi's Patent Application for Spectral Imaging of Deep Tissue 2Anavex advances drug candidate for treatment of Alzheimer's disease 2Anavex advances drug candidate for treatment of Alzheimer's disease 3Anavex advances drug candidate for treatment of Alzheimer's disease 4Anavex advances drug candidate for treatment of Alzheimer's disease 5
    (Date:10/16/2014)... , October 16, 2014 NXT-ID, Inc. ... the "Company"), a biometric authentication company focused on the ... leading edge technologies including Wocket™, the Smart Wallet, at ... Conferenece. FiRe is a leading global conference on the ... Hosted by Mark Anderson , founder and publisher ...
    (Date:10/15/2014)... to an unexpected extent. The outbreak does not follow ... shows a new disease dynamic in regions, where it ... German National Academy of Sciences Leopoldina, acatech – the ... of the German Academies of Sciences and Humanities have ... In the statement the academies call for the following ...
    (Date:10/14/2014)... prostate cancer tumors scavenge and hoard copper that is ... may be a fatal weakness. , Researchers at ... cancer cells by delivering a trove of copper along ... brimming with the mineral, leaving non-cancer cells healthy. , ... available for other uses, could soon be tested in ...
    Breaking Biology News(10 mins):NXT-ID Inc. to Present at 13th Annual FiRe Conference 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 3Academies call for consequences from the Ebola virus epidemic 2Academies call for consequences from the Ebola virus epidemic 3Academies call for consequences from the Ebola virus epidemic 4Academies call for consequences from the Ebola virus epidemic 5Prostate cancer's penchant for copper may be a fatal flaw 2
    ... characterise their Zap-It! product, which uses the tiny electric ... itching caused by insect bites - such as those from ... that is based around a similar piezoelectric mechanism to that ... a medical device, currently available to buy in high street ...
    ... Molecular biologist Ichiro Matsumoto, Ph.D., of the Monell Center, ... Young Investigators in Gustation, awarded annually by the Association ... who is an emerging leader in the field of ... the understanding of the organization, relationships and connectivity of ...
    ... of the potentially deadly antibiotic-resistant bacterium known as MRSA ... a new study involving two Northern Arizona University researchers., ... for Microbial Genetics and Genomics, and Lance Price, NAU ... Microbiology and Environmental Health at the Translational Genomics Research ...
    Cached Biology News:Zapping mosquito bites 2Evolution of staph 'superbug' traced between humans and food animals 2
    ...
    ...
    Immunogen: Peptide corresponding to amino acid residues from the N-terminal region of human thyroid hormone receptor, alpha1/alpha2-isotype. Storage: -20 C, Avoid Freeze/Thaw Cycles...
    Antibodies were affinity purified using epitopes specific to QKI immobilized on solid support....
    Biology Products: